TriVascular, Inc. Begins U.S.

Pivotal Study of the

Ovation™ Abdominal Stent Graft System

Study to Support Application for U.S. Market Approval

Santa Rosa, CA, May 3, 2010 – TriVascular, Inc. of Santa Rosa, California, announced
today the first U.S. clinical study implant of its Ovation™ Abdominal Stent Graft. The
innovative, low-profile system is designed to expand the patient population suitable for
endovascular aortic repair (EVAR) by addressing a wider range of diseased anatomy.
Gregory Mishkel, MD, Co-Director Cardiac Catheterization Lab, Prairie Heart Institute at
St. John's Hospital in Springfield, Illinois performed the first case.

“The Ovation abdominal stent graft performed very well and was easy to use,” said Dr.
Mishkel. “We are excited to participate in the clinical study of this novel, next-generation
device. The significantly reduced profile of the delivery catheter will increase the pool of
patients to whom I can offer EVAR.”

The U.S. Investigational Device Exemption (IDE) study will evaluate the safety and
effectiveness of the Ovation Abdominal Stent Graft System. The National Principal
Investigator for the trial is Manish Mehta, MD, MPH, Director of Endovascular Services at
The Vascular Institute for Health & Disease in Albany, New York.

"I am pleased to be partnering with TriVascular on this important clinical effort,” said Dr.
Mehta. “I believe the Ovation Abdominal Stent Graft has the potential to considerably
improve upon currently available stent grafts, particularly in its ability to accommodate
complex aortic necks and difficult iliac access. With the Ovation Abdominal Stent Graft
System we may be able to offer minimally invasive EVAR to a broader group of patients.”

“We are tremendously excited to begin U.S. clinical work,” said Mike Chobotov, Ph.D.,
President and CEO of TriVascular, Inc. “We are encouraged by the enthusiasm of our
clinical investigators and feel fortunate to be partnering with some of the top physicians
in the country. Furthermore, we are thrilled to help provide an advanced solution for
patients suffering with aortic disease in the United States.”

The Ovation Abdominal Stent Graft System is an investigational device and currently not
approved for sale.

About TriVascular, Inc. - TriVascular’s initial product offerings are novel endovascular
grafts focused on significantly advancing EVAR. Building upon partnerships with thought
leading clinicians worldwide, TriVascular’s products are designed to address unmet
clinical needs and expand the pool of patients who are candidates for EVAR. Based in
Santa Rosa, California, TriVascular offers highly talented, motivated individuals the
opportunity to positively impact global healthcare.

830-0009-01rA
3910 Brickway Blvd., Santa Rosa, CA 95403 Fax 707-543-8600 707-543-8800